CJC-1295 with DAC Dosing For the long-acting CJC-1295 with DAC variant (completely different from no DAC): Research Dose: 30-60mcg per kilogram of body weight Frequency: Once or twice weekly (due to extended half-life) Example: A 90kg (200lb) person = 2,700-5,400mcg per injection Duration: Ongoing with medical monitoring Source: PubMed Clinical Study - "Subcutaneous administration of CJC-1295 resulted in sustained, dose-dependent increases in GH and IGF-I levels in healthy adults and was safe and relatively well tolerated, particularly at doses of 30 or 60 microg/kg" Important: This is a clinical research dose for CJC-1295 WITH DAC
To ensure adequate statistical power, a priori power analysis was conducted using G*Power software (version 3.1) based on previously observed effect sizes from pilot studies and similar experimental models in the literature
Overall, these findings indicate that reductions in GPx3 abundance trends with disease severity with stage 1 having the highest mean levels of GPx3 (1.99 g/ml 0.73 g/ml) and the highest K1/U1 ratio (0.86), followed by the stage 2 with a mean of 1.2 g/ml 0.54 g/ml and average K2/U2 ratio of 0.67, with the most severe form of konzo, stage 3, displaying the largest reduction in average protein abundance (mean: 1.15 g/ml 0.58 g/ml) and the lowest K3/U3 ratio of 0.59 (Supplementary Data 1)
[Epub ahead of print])
Rights reserved 2 Vol:.(1234567890) | (2024) 14:15153 | www.nature.com/scientificreports/ e second step involves adding glycine to -EC to form GSH, catalyzed by glutathione synthetase (GSS)10
M., Atayee, R